 Recently, Vir Biotechnology Inc NASDAQ: VIR announced updates on its expansive hepatitis portfolio, including VIR-2218 which is part of a collaboration with Alnylam Pharmaceuticals Inc NASDAQ: ALNY, and VIR-3434, a monoclonal antibody mAb. The key highlight of. 